Juvlabs
juvlabs.com
Drug Discovery
Prescription Drugs
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$121.9M
4 rounds on record
Latest round
$9.5M
Convertible Note · Dec 2020 · 5 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
70 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 4, 2021
New executive David Roblin, Executive Officer · SEC Form D
Dec 17, 2020
Raised a round Convertible Note $9.5M · SEC Form D
Apr 17, 2020
New executive David Ellam, Executive Officer · SEC Form D
Apr 29, 2019
Raised a round Venture round $56.9M · SEC Form D
Jul 6, 2018
Board appointment Karim Hakimzadeh, Director · SEC Form D
Jun 20, 2018
Raised a round Venture round $53.1M · SEC Form D
Dec 1, 2017
Raised a round Venture round $2.5M · SEC Form D
2017
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Dec 2020 | $9.5M | — | SEC Form D |
| Venture round | Apr 2019 | $56.9M | — | SEC Form D |
| Venture round | Jun 2018 | $53.1M | — | SEC Form D |
| Venture round | Dec 2017 | $2.5M | — | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
James MellonExecutive Officer, DirectorSEC Form D
Declan DooganExecutive Officer, DirectorSEC Form D
Gregory BaileyExecutive Officer, DirectorSEC Form D
Denham EkeDirectorSEC Form D
David EllamExecutive OfficerSEC Form D
Alex PickettExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Retro Biosciences develops therapies that target aging biology to extend healthy human lifespan by 10 years.
Mapping Biology to Precise Medicines The best therapeutics are built around the best targets. By analyzing massive datasets from individual…
Transforming Eye Care With Precision Medicine. Age-related macular degeneration (AMD) impacts one in eight people over the age of fifty and…
Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at…
Highlights. Vincere makes new medicines to treat age-related diseases including Parkinson's and Kidney disease.
Advancing medicines to restore homeostasis. Cajal Therapeutics is developing novel medicines for serious diseases, including anemias of…
News
Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in
Read more
Report
Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy
Read more
Report
Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City's Life Science Innovation Cluster
Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City Jennings-Brown will drive AI and technology strategy and lead the development of capabilities enab
Read more
Report
Richards interview to Jo Shorthouse
There's still capital out there - it's just coming from new directions. Our CEO, Richard Marshall CBE, shares his insights on the evolving biotech funding landscape and where companies like Juvenescence are finding opportunity amid the VC pullback by forg
Read more
Report
New Medicines for the Healthspan Revolution M42
https://www.youtube.com/watch?v=FKrjMToSbjw
Read more
Report
Demystifying Biotechnology: A Deep Dive into Juvenescence M42
https://www.youtube.com/watch?v=p_GDB_YwAIg
Read more
Report
Greg Bailey: Biotech can add another 10 healthy years to your life
https://www.youtube.com/watch?v=_PwOWvX1UIE
Read more
Report
Juvenescence: Think aging up, rather than disease down
https://www.youtube.com/watch?v=bOLVqSX2-VU
Read more
Report
Presenting at several conferences in the UAE
Juvenescence has carried positive momentum into 2026 following a series of invigorating conferences in hashtag#AbuDhabi, where our team joined discussions on shaping the future of hashtag#longevity and advancing hashtag#healthspan. At the Revive ME Longev
Read more
Report
Eric Verdin, our collaborator in the Buck institute presents data on our compound
We were pleased to attend the Longevity Summit 2025 at the Buck Institute for Research on Aging, a vibrant gathering of leaders across aging science, biotechnology, and translational research, united by a shared commitment to advancing healthy aging. We w
Read more
Report
Show more news
People
James Mellon
Executive Officer, Director
Declan Doogan
Executive Officer, Director
Gregory Bailey
Executive Officer, Director
Denham Eke
Director
David Ellam
Executive Officer
Alex Pickett
Executive Officer
Susan Bergin
Executive Officer
David Roblin
Executive Officer
Colin Watts
Executive Officer
Karim Hakimzadeh
Director
Jean-Christophe Renondin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Douglas
Isle of Man
HQ
50-200 est. staff